Definium Therapeutics (NASDAQ:DFTX) Sees Large Volume Increase – Here’s Why

Definium Therapeutics, Inc. (NASDAQ:DFTX) saw strong trading volume on Monday . 1,217,849 shares traded hands during mid-day trading, a decline of 34% from the previous session’s volume of 1,855,422 shares.The stock last traded at $22.89 and had previously closed at $23.55.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Oppenheimer reiterated an “outperform” rating and issued a $40.00 target price on shares of Definium Therapeutics in a report on Thursday, April 23rd. HC Wainwright increased their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research assumed coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price for the company. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $37.92.

Definium Therapeutics Stock Performance

The company has a market cap of $2.24 billion, a P/E ratio of -9.04 and a beta of 2.37. The company’s 50-day moving average is $21.84 and its two-hundred day moving average is $17.54. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities analysts predict that Definium Therapeutics, Inc. will post -2.3 EPS for the current year.

Institutional Investors Weigh In On Definium Therapeutics

Several institutional investors have recently added to or reduced their stakes in DFTX. Royal Bank of Canada lifted its holdings in Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning lifted its holdings in Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after acquiring an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.